MX2018006157A - Dispositivos y composiciones de administracion transdermica resistentes al abuso que comprenden un agonista de opioide y un derivado de n-oxido administrado por la ruta no transdermica de un antagonista de opioide para el tratamiento del dolor. - Google Patents

Dispositivos y composiciones de administracion transdermica resistentes al abuso que comprenden un agonista de opioide y un derivado de n-oxido administrado por la ruta no transdermica de un antagonista de opioide para el tratamiento del dolor.

Info

Publication number
MX2018006157A
MX2018006157A MX2018006157A MX2018006157A MX2018006157A MX 2018006157 A MX2018006157 A MX 2018006157A MX 2018006157 A MX2018006157 A MX 2018006157A MX 2018006157 A MX2018006157 A MX 2018006157A MX 2018006157 A MX2018006157 A MX 2018006157A
Authority
MX
Mexico
Prior art keywords
opioid
pain
compositions
transdermal delivery
treatment
Prior art date
Application number
MX2018006157A
Other languages
English (en)
Inventor
Whitelock Steve
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MX2018006157A publication Critical patent/MX2018006157A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un dispositivo de administración transdérmica que comprende una composición farmacéutica, donde la composición comprende un derivado de N-óxido de un antagonista de opioide o una sal del mismo y un agonista de opioide o una sal del mismo.
MX2018006157A 2015-11-19 2016-11-18 Dispositivos y composiciones de administracion transdermica resistentes al abuso que comprenden un agonista de opioide y un derivado de n-oxido administrado por la ruta no transdermica de un antagonista de opioide para el tratamiento del dolor. MX2018006157A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1520390.4A GB201520390D0 (en) 2015-11-19 2015-11-19 Composition
PCT/GB2016/053600 WO2017085502A1 (en) 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain

Publications (1)

Publication Number Publication Date
MX2018006157A true MX2018006157A (es) 2019-04-04

Family

ID=55133015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006157A MX2018006157A (es) 2015-11-19 2016-11-18 Dispositivos y composiciones de administracion transdermica resistentes al abuso que comprenden un agonista de opioide y un derivado de n-oxido administrado por la ruta no transdermica de un antagonista de opioide para el tratamiento del dolor.

Country Status (14)

Country Link
US (1) US20180344726A1 (es)
EP (1) EP3377048B1 (es)
JP (1) JP2018534319A (es)
KR (1) KR20180074797A (es)
CN (1) CN108601747A (es)
AU (1) AU2016355113A1 (es)
BR (1) BR112018009886A2 (es)
CA (1) CA3005775A1 (es)
ES (1) ES2799516T3 (es)
GB (1) GB201520390D0 (es)
IL (1) IL259457A (es)
MX (1) MX2018006157A (es)
SG (1) SG11201803913RA (es)
WO (1) WO2017085502A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722928A (en) * 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
PT1255547E (pt) * 2000-02-08 2008-11-24 Euro Celtique Sa Composições de libertação controlada contendo agonistas e antagonistas opióides
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
CN101455649B (zh) * 2002-06-10 2014-02-26 欧洲凯尔特公司 防止所含活性剂被误用的经皮给药器的处置系统
RS50963B (sr) * 2004-02-23 2010-10-31 Euro-Celtique S.A. Opioidni transdermalni preparat otporan na zloupotrebu
WO2008070462A2 (en) * 2006-11-22 2008-06-12 Progenics Pharmaceuticals, Inc. N-oxides of 4,5-epoxy-morphinanium analogs
WO2009067275A1 (en) * 2007-11-21 2009-05-28 Progenics Pharmaceuticals, Inc N-oxides of 4,5-epoxy-morphinanium analogs
JP2011515495A (ja) * 2008-03-26 2011-05-19 オールトランツ インコーポレイティド オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑制経皮製剤
US8829020B2 (en) * 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
EP2552425B1 (en) * 2010-04-02 2016-07-27 Buzzz Pharmaceuticals Limited Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists

Also Published As

Publication number Publication date
AU2016355113A1 (en) 2018-05-24
GB201520390D0 (en) 2016-01-06
CA3005775A1 (en) 2017-05-26
EP3377048A1 (en) 2018-09-26
KR20180074797A (ko) 2018-07-03
US20180344726A1 (en) 2018-12-06
WO2017085502A1 (en) 2017-05-26
ES2799516T3 (es) 2020-12-18
IL259457A (en) 2018-07-31
JP2018534319A (ja) 2018-11-22
EP3377048B1 (en) 2020-04-22
CN108601747A (zh) 2018-09-28
SG11201803913RA (en) 2018-06-28
BR112018009886A2 (pt) 2018-11-13

Similar Documents

Publication Publication Date Title
SG10201807625PA (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
GB2538682A (en) Nasal drug products and methods of their use
IL291155A (en) Drug delivery device
IL291004A (en) Drug delivery device
IL275102A (en) Devices and methods for administering a precise dose
PL3426250T3 (pl) Leczenie pacjenta lekiem będącym substratem CYP3A4 przeciwwskazanym do jednoczesnego podawania z silnym inhibitorem CYP3A4
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
IL291415A (en) Drug delivery device
IL291295A (en) Drug delivery device
MX2023006706A (es) Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos.
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
IL268385B (en) Drug delivery devices and drug delivery methods
PH12019500326A1 (en) Combination of fxr agonists
IL273735A (en) A device for transdermal delivery of dextromethorphan
ZA202007757B (en) Localised transdermal iontophoretic drug delivery system
PH12017500436A1 (en) Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence
IL279127A (en) Dispensing devices for drug administration
GB2578712B (en) Apparatus and methods for the transdermal delivery of active agents
MX2021006102A (es) Suministro mejorado de agentes grandes.
IL291154A (en) Drug delivery device
MX2018005439A (es) Compuestos oxadiazoespiricos para el tratamiento del abuso y la adiccion a las drogas.
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash
EP3876938A4 (en) COMPOSITIONS AND METHODS OF ADMINISTRATION OF OPIOID ANTAGONISTS
EP3233081A4 (en) Transdermal drug delivery device including fentanyl